Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089 · View on ClinicalTrials.gov ↗
Study Summary
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Conditions Studied
Interventions
- DRUG Secretin
- DIAGNOSTIC_TEST MRI
- OTHER Tumor marker gene test with CA19-9
Study Locations (9)
New York
- NYU Langone Medical Center — New York
- Columbia University Medical Center — New York
Pennsylvania
- University of Pennsylvania — Philadelphia
- University of Pittsburgh — Pittsburgh
Connecticut
- Yale University — New Haven
Maryland
- Johns Hopkins Hospital — Baltimore
Massachusetts
- Dana Farber Cancer Center, Harvard University — Boston
Michigan
- University of Michigan — Ann Arbor
Ohio
- Case Comprehensive Cancer Center, Case Western Medical Reserve — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,000 participants |
| Start Date | 2014-01-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000089
The ClinicalTrials.gov registry entry for NCT02000089 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 9,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,517 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 3 interventions — of which Secretin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02000089 reports 9 study locations spanning 7 distinct geographic areas — top geographies include New York, Pennsylvania, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02000089 about?
NCT02000089 is a clinical study titled "The Cancer of the Pancreas Screening-5 CAPS5)Study". Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
What is the current status of trial NCT02000089?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 9,000 participants. The study started on 2014-01-06. Estimated completion is 2029-06.
What conditions does trial NCT02000089 study?
This clinical trial studies the following conditions: Pancreas Cancer, Lynch Syndrome, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02000089?
The interventions under investigation include: Secretin (DRUG), MRI (DIAGNOSTIC_TEST), Tumor marker gene test with CA19-9 (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02000089?
This trial is sponsored by Johns Hopkins University, which has 1,517 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02000089 being conducted?
This trial has 9 study locations across Connecticut, Maryland, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.